{
  "id": 5435879,
  "title": "BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?",
  "url": "https://urgent.news/2026/09/03/biontech-vs-moderna-which-is-the-better-cancer-vaccine-stock-to-buy-5435879",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T21:30:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/03/biontech-vs-moderna-which-is-the-better-cancer-vac/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "BioNTech and Moderna, two companies that came to prominence during the COVID-19 pandemic, have seen their financial performance decline as the crisis subsided. These mRNA-based vaccine developers have struggled to keep up with the broader market over the past five years. However, there may be a promising future ahead for both companies as they move forward with their vaccine candidates.\n\nBioNTech, known for its deep pipeline of candidates, has a particularly exciting molecule in the works called pumitamig. This drug is being developed in collaboration with Bristol Myers Squibb (NYSE: BMY). What sets pumitamig apart is its potential to challenge Merck's (NYSE: MRK) blockbuster cancer medication, Keytruda. Merck's Keytruda has been the world's best-selling cancer drug, so a competitor like pumitamig could significantly impact Merck's market position.\n\nBioNTech is currently testing pumitamig in several potential cancer indications, with lung cancer being the top priority. Given that lung cancer is the leading cause of cancer-related deaths, success in this area could be particularly significant. Positive results from pumitamig clinical trials could lead to a substantial boost in BioNTech's stock price.",
  "summary": "Both have attracted considerable attention from Wall Street recently.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?",
        "url": "https://urgent.news/2026/09/03/biontech-vs-moderna-which-is-the-better-cancer-vaccine-stock-to-buy",
        "published": "2026-09-03T21:50:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}